HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ifetroban

thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative
Also Known As:
BMS 180291; BMS-180291; BMS180291; Benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1S-(exo,exo))-
Networked: 16 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Banovich, Nicholas E: 1 article (01/2022)
2. Blackwell, Timothy S: 1 article (01/2022)
3. Camarata, Jane E: 1 article (01/2022)
4. Carrier, Erica J: 1 article (01/2022)
5. Chen, Jingyuan: 1 article (01/2022)
6. Chen, Xinping: 1 article (01/2022)
7. Freeman, Michael L: 1 article (01/2022)
8. Gokey, Jason J: 1 article (01/2022)
9. Gulleman, Peter: 1 article (01/2022)
10. Gutor, Sergey: 1 article (01/2022)

Related Diseases

1. Myocardial Ischemia (Ischemic Heart Diseases)
2. Ischemia
3. Cardiomyopathies (Cardiomyopathy)
4. Muscular Dystrophies (Muscular Dystrophy)
5. Hypertension (High Blood Pressure)
01/01/2001 - "We describe studies on the mechanisms of how ifetroban relaxes experimentally contracted isolated vascular tissue, and on the effects of ifetroban on myocardial ischemia, hypertension, stroke, thrombosis, and its effects on platelets. "
11/01/1998 - "These observations suggest that a mechanism involving nitric oxide and potassium channels facilitates the reduction in basal tone produced by ifetroban in aortic rings of rats with aortic coarctation-induced hypertension."
10/01/1996 - "These studies assessed the antihypertensive response to administration of the AT1 receptor antagonist losartan (20 mg.kg-1.day-1), the TxA2/PGH2 receptor antagonist ifetroban (20 mg.kg-1.day-1) or vehicle given for 3 days to rats with early (2-4 wk postclip), intermediate (10-12 wk postclip), and late (36-42 wk post-clip) 2K,1C hypertension and to two control groups of rats corresponding in age to the early or intermediate and the late 2K,1C groups. "
02/01/1996 - "Experiments were performed to determine the effect of chronic therapy with the potent and long-acting thromboxane (TX) A2/prostaglandin endoperoxide (TP) receptor antagonist, ifetroban, on hypertension development and the incidence of stroke in stroke-prone spontaneously hypertensive rats (SHRSP). "
11/01/1998 - "This study was designed to investigate involvement of potassium channels in the action of nitric oxide facilitating reduction of basal tone by thromboxane A2/prostaglandin H2 receptor blockade with ifetroban in rings of thoracic aorta taken from rats with aortic coarctation-induced hypertension. "

Related Drugs and Biologics

1. Thromboxane A2 (A2, Thromboxane)
2. Prostaglandins
3. Thromboxane Receptors (Thromboxane Receptor)
4. Aspirin (Acetylsalicylic Acid)
5. Prostaglandin H2 Thromboxane A2 Receptors
6. Prostaglandin H2 (PGH(2))
7. Losartan (Cozaar)
8. Potassium Channels (Potassium Channel)
9. Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
10. Nitric Oxide (Nitrogen Monoxide)

Related Therapies and Procedures

1. Therapeutics